Glioma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Denovo, Pfizer, Chimerix, AiVita, Ascletis, Immunomic, Roche, Vigeo

Glioma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Denovo, Pfizer, Chimerix, AiVita, Ascletis, Immunomic, Roche, Vigeo
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 190+ key pharma and biotech companies are working on 130+ pipeline drugs in the Glioma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Glioma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Glioma Market. 

The Glioma Pipeline report embraces in-depth commercial, regulatory, and Glioma clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Glioma drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Glioma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Glioma treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Glioma therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Glioma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Glioma drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Glioma therapeutic market.

Glioma Therapeutics Landscape

Treatment for Glioma usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since HGGs develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection – removing as much of the tumor as possible while preserving the patient’s brain function and sparing healthy tissues. Residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy, after surgery. Radiation therapy and chemotherapy usually follow surgery once the diagnosis or name of the tumor is determined. These treatments are called adjuvant treatments.

Recently in June 2022, Novartis announced that the US FDA granted accelerated approval to Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment.

The pipeline of glioma involves drugs with a varied mechanism of action along with different routes of administration, ranging from oral, intravenous, intratumoral, subcutaneous, etc. There are approx. 190+ key companies developing therapies for Glioma Disease. It is interesting to note that the emerging market of HGG includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, as well as four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401), DAY101, AB-218, mirdametinib, AG- 881 by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, Day One Biopharmaceuticals, AnHeart Therapeutic, SpringWorks Therapeutics, Servier respectively. Currently, Denovo BioPharma is leading the therapeutics market with its Glioma Disease drug candidates in the most advanced stage of clinical development.

Glioma Companies Actively Working in the Therapeutic Market Include:

Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals, and many others.

Emerging and Marketed Glioma Drugs Covered in the Report Include:

  • Tofacitinib: Pfizer

  • Enzastaurin: Denovo BioPharma

  • MDNA55: Medicenna Therapeutics, Inc.

  • Sym004: Symphogen A/S

  • MN-166: MediciNova

  • AVASTIN: Genentech

  • TEMODAR (temozolomide): Merck

  • Ofranergene obadenovec (VB-111): VBL Therapeutics

  • SurVaxM: MimiVax

  • Vorasidenib (AG-881): Servier

  • Tovorafenib (DAY101): Day One Biopharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Glioma Companies Working in the Market @

Analysis of Emerging Glioma Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Glioma Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Molecule Types

Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

Learn How the Glioma Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Glioma Treatment Patterns

4. Glioma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Glioma Late Stage Products (Phase-III)

7. Glioma Mid-Stage Products (Phase-II)

8. Glioma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Glioma Discontinued Products

13. Glioma Product Profiles

14. Major Glioma Companies in the Market

15. Key Products in the Glioma Therapeutics Segment

16. Dormant and Discontinued Products

17. Glioma Unmet Needs

18. Glioma Future Perspectives

19. Glioma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Diverticulitis Market

“Diverticulitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diverticulitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Diverticulitis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States